ACTRIMS 2024 | Transitioning from IV anti-CD20 therapy to ublituximab in MS: insights from ENHANCE

Barry Singer, MD, The MS Center for Innovations in Care, St. Louis, MO, discusses data from the ENHANCE study (NCT05877963), which evaluates the efficacy and tolerability of transitioning from intravenous (IV) anti-CD20 therapy to ublituximab in the treatment of multiple sclerosis (MS). Patients who had received prior anti-CD20 therapy were excluded from the major clinical trials of ublituximab, necessitating investigation into the best transition approach and if the initial 150mg dose starting infusion could be eliminated in this patient population. The study consisted of two cohorts; cohort 1 received a 2-hour infusion of 450mg ublituximab and cohort 2 received a 1-hour infusion of 450mg ublituximab. The trial found no significant infusion reactions in cohort 1 and 81% of patients in cohort 2 had no significant reactions, with the others having only mild reactions. This interim data supports the safety and efficacy of eliminating the low-dose starting infusion in these patients. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.